Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide

AF-QOL study investigators

Research output: Contribution to journalArticle

Abstract

Background The therapeutic goals of atrial fibrillation (AF) patients are to reduce symptoms and prevent severe complications associated with AF. This study compared the efficacy of flecainide versus pilsicainide in reducing the frequency of AF and improving quality of life (QOL) in symptomatic paroxysmal AF patients without structural heart disease. Methods The Atrial Fibrillation and Quality Of Life (AF-QOL) study was a prospective, multicenter, randomized, open-label crossover study that compared flecainide and pilsicainide as antiarrhythmic drug therapy. Patients were randomized to receive 3 months of treatment with flecainide twice daily or pilsicainide 3 times daily. Each treatment consisted of a dose-finding phase (weeks 1–4) and an efficacy phase (weeks 5–12). Forty-three patients completed the trial. The main outcome was the number of days with documented AF episodes using a patient-operated electrocardiogram. QOL questionnaires (SF-36 and AF-specific QOL scores) were also completed. Results The median (range) AF frequencies (days/8 weeks) were 2 (0–50) in the flecainide treatment group and 1 (0–54) in the pilsicainide treatment group (no significant between-group difference). No significant difference in the first recurrence of AF during the efficacy phase was noted between flecainide and pilsicainide treatments. The frequency and severity scores of AF-related symptoms improved from baseline to the end of the treatment periods. No significant differences in SF-36 or AF-related QOL scores were noted between the treatment groups. Conclusions This study found no difference in AF frequency or QOL between symptomatic paroxysmal AF patients who received flecainide or pilsicainide.

Original languageEnglish
Pages (from-to)310-317
Number of pages8
Journaljournal of arrhythmia
Volume33
Issue number4
DOIs
Publication statusPublished - 01-08-2017

Fingerprint

Flecainide
Cross-Over Studies
Atrial Fibrillation
Quality of Life
Recurrence
Therapeutics
pilsicainide
Anti-Arrhythmia Agents

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{779aa51b9b14463a8e69896791018ef7,
title = "Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide",
abstract = "Background The therapeutic goals of atrial fibrillation (AF) patients are to reduce symptoms and prevent severe complications associated with AF. This study compared the efficacy of flecainide versus pilsicainide in reducing the frequency of AF and improving quality of life (QOL) in symptomatic paroxysmal AF patients without structural heart disease. Methods The Atrial Fibrillation and Quality Of Life (AF-QOL) study was a prospective, multicenter, randomized, open-label crossover study that compared flecainide and pilsicainide as antiarrhythmic drug therapy. Patients were randomized to receive 3 months of treatment with flecainide twice daily or pilsicainide 3 times daily. Each treatment consisted of a dose-finding phase (weeks 1–4) and an efficacy phase (weeks 5–12). Forty-three patients completed the trial. The main outcome was the number of days with documented AF episodes using a patient-operated electrocardiogram. QOL questionnaires (SF-36 and AF-specific QOL scores) were also completed. Results The median (range) AF frequencies (days/8 weeks) were 2 (0–50) in the flecainide treatment group and 1 (0–54) in the pilsicainide treatment group (no significant between-group difference). No significant difference in the first recurrence of AF during the efficacy phase was noted between flecainide and pilsicainide treatments. The frequency and severity scores of AF-related symptoms improved from baseline to the end of the treatment periods. No significant differences in SF-36 or AF-related QOL scores were noted between the treatment groups. Conclusions This study found no difference in AF frequency or QOL between symptomatic paroxysmal AF patients who received flecainide or pilsicainide.",
author = "{AF-QOL study investigators} and Tsuyoshi Shiga and Koichiro Yoshioka and Eiichi Watanabe and Eiichi Watanabe and Masahiro Yagi and Yasuo Okumura and Naoki Matsumoto and Kengo Kusano and Chikara Oshiro and Takanori Ikeda and Naohiko Takahashi and Takashi Komatsu and Atsushi Suzuki and Tsuyoshi Suzuki and Yasuto Sato and Takeshi Yamashita",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.joa.2017.03.005",
language = "English",
volume = "33",
pages = "310--317",
journal = "Journal of Arrhythmia",
issn = "1880-4276",
publisher = "Elsevier BV",
number = "4",

}

Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients : A crossover study of flecainide and pilsicainide. / AF-QOL study investigators.

In: journal of arrhythmia, Vol. 33, No. 4, 01.08.2017, p. 310-317.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients

T2 - A crossover study of flecainide and pilsicainide

AU - AF-QOL study investigators

AU - Shiga, Tsuyoshi

AU - Yoshioka, Koichiro

AU - Watanabe, Eiichi

AU - Watanabe, Eiichi

AU - Yagi, Masahiro

AU - Okumura, Yasuo

AU - Matsumoto, Naoki

AU - Kusano, Kengo

AU - Oshiro, Chikara

AU - Ikeda, Takanori

AU - Takahashi, Naohiko

AU - Komatsu, Takashi

AU - Suzuki, Atsushi

AU - Suzuki, Tsuyoshi

AU - Sato, Yasuto

AU - Yamashita, Takeshi

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background The therapeutic goals of atrial fibrillation (AF) patients are to reduce symptoms and prevent severe complications associated with AF. This study compared the efficacy of flecainide versus pilsicainide in reducing the frequency of AF and improving quality of life (QOL) in symptomatic paroxysmal AF patients without structural heart disease. Methods The Atrial Fibrillation and Quality Of Life (AF-QOL) study was a prospective, multicenter, randomized, open-label crossover study that compared flecainide and pilsicainide as antiarrhythmic drug therapy. Patients were randomized to receive 3 months of treatment with flecainide twice daily or pilsicainide 3 times daily. Each treatment consisted of a dose-finding phase (weeks 1–4) and an efficacy phase (weeks 5–12). Forty-three patients completed the trial. The main outcome was the number of days with documented AF episodes using a patient-operated electrocardiogram. QOL questionnaires (SF-36 and AF-specific QOL scores) were also completed. Results The median (range) AF frequencies (days/8 weeks) were 2 (0–50) in the flecainide treatment group and 1 (0–54) in the pilsicainide treatment group (no significant between-group difference). No significant difference in the first recurrence of AF during the efficacy phase was noted between flecainide and pilsicainide treatments. The frequency and severity scores of AF-related symptoms improved from baseline to the end of the treatment periods. No significant differences in SF-36 or AF-related QOL scores were noted between the treatment groups. Conclusions This study found no difference in AF frequency or QOL between symptomatic paroxysmal AF patients who received flecainide or pilsicainide.

AB - Background The therapeutic goals of atrial fibrillation (AF) patients are to reduce symptoms and prevent severe complications associated with AF. This study compared the efficacy of flecainide versus pilsicainide in reducing the frequency of AF and improving quality of life (QOL) in symptomatic paroxysmal AF patients without structural heart disease. Methods The Atrial Fibrillation and Quality Of Life (AF-QOL) study was a prospective, multicenter, randomized, open-label crossover study that compared flecainide and pilsicainide as antiarrhythmic drug therapy. Patients were randomized to receive 3 months of treatment with flecainide twice daily or pilsicainide 3 times daily. Each treatment consisted of a dose-finding phase (weeks 1–4) and an efficacy phase (weeks 5–12). Forty-three patients completed the trial. The main outcome was the number of days with documented AF episodes using a patient-operated electrocardiogram. QOL questionnaires (SF-36 and AF-specific QOL scores) were also completed. Results The median (range) AF frequencies (days/8 weeks) were 2 (0–50) in the flecainide treatment group and 1 (0–54) in the pilsicainide treatment group (no significant between-group difference). No significant difference in the first recurrence of AF during the efficacy phase was noted between flecainide and pilsicainide treatments. The frequency and severity scores of AF-related symptoms improved from baseline to the end of the treatment periods. No significant differences in SF-36 or AF-related QOL scores were noted between the treatment groups. Conclusions This study found no difference in AF frequency or QOL between symptomatic paroxysmal AF patients who received flecainide or pilsicainide.

UR - http://www.scopus.com/inward/record.url?scp=85020085482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020085482&partnerID=8YFLogxK

U2 - 10.1016/j.joa.2017.03.005

DO - 10.1016/j.joa.2017.03.005

M3 - Article

AN - SCOPUS:85020085482

VL - 33

SP - 310

EP - 317

JO - Journal of Arrhythmia

JF - Journal of Arrhythmia

SN - 1880-4276

IS - 4

ER -